HRP20030103A2 - Substituted imidazoles as tafia inhibitors - Google Patents
Substituted imidazoles as tafia inhibitors Download PDFInfo
- Publication number
- HRP20030103A2 HRP20030103A2 HR20030103A HRP20030103A HRP20030103A2 HR P20030103 A2 HRP20030103 A2 HR P20030103A2 HR 20030103 A HR20030103 A HR 20030103A HR P20030103 A HRP20030103 A HR P20030103A HR P20030103 A2 HRP20030103 A2 HR P20030103A2
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- preparation
- hydrogen
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims description 105
- 150000002460 imidazoles Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 397
- 238000002360 preparation method Methods 0.000 claims description 243
- 239000000203 mixture Substances 0.000 claims description 138
- 238000000034 method Methods 0.000 claims description 127
- 239000001257 hydrogen Substances 0.000 claims description 63
- 229910052739 hydrogen Inorganic materials 0.000 claims description 63
- 238000011282 treatment Methods 0.000 claims description 58
- 150000003839 salts Chemical class 0.000 claims description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 35
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 34
- 229940002612 prodrug Drugs 0.000 claims description 34
- 239000000651 prodrug Substances 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 208000007536 Thrombosis Diseases 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 29
- 230000002265 prevention Effects 0.000 claims description 28
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 27
- 239000012453 solvate Substances 0.000 claims description 25
- 125000002947 alkylene group Chemical group 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 229920006395 saturated elastomer Polymers 0.000 claims description 22
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 21
- 125000001188 haloalkyl group Chemical group 0.000 claims description 21
- 102000009123 Fibrin Human genes 0.000 claims description 20
- 108010073385 Fibrin Proteins 0.000 claims description 20
- 229950003499 fibrin Drugs 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 230000003176 fibrotic effect Effects 0.000 claims description 19
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 19
- 230000002785 anti-thrombosis Effects 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 18
- 201000001320 Atherosclerosis Diseases 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 16
- 101800004538 Bradykinin Proteins 0.000 claims description 15
- 108090000201 Carboxypeptidase B2 Proteins 0.000 claims description 15
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 15
- 239000003146 anticoagulant agent Substances 0.000 claims description 15
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 15
- 208000006011 Stroke Diseases 0.000 claims description 14
- 238000001356 surgical procedure Methods 0.000 claims description 14
- 230000008901 benefit Effects 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 13
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 12
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 11
- 206010002383 Angina Pectoris Diseases 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 10
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 10
- 208000010125 myocardial infarction Diseases 0.000 claims description 10
- 238000011477 surgical intervention Methods 0.000 claims description 10
- 102100035023 Carboxypeptidase B2 Human genes 0.000 claims description 9
- 206010053567 Coagulopathies Diseases 0.000 claims description 9
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 9
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 8
- 206010039580 Scar Diseases 0.000 claims description 8
- 206010047249 Venous thrombosis Diseases 0.000 claims description 8
- 206010003246 arthritis Diseases 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 230000001732 thrombotic effect Effects 0.000 claims description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 7
- 206010040047 Sepsis Diseases 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 208000015294 blood coagulation disease Diseases 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 6
- 208000005189 Embolism Diseases 0.000 claims description 6
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 6
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 6
- 229960004676 antithrombotic agent Drugs 0.000 claims description 6
- 206010003119 arrhythmia Diseases 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 230000000019 pro-fibrinolytic effect Effects 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 206010008088 Cerebral artery embolism Diseases 0.000 claims description 5
- 206010008132 Cerebral thrombosis Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 201000009273 Endometriosis Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims description 5
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
- 208000008487 fibromuscular dysplasia Diseases 0.000 claims description 5
- 238000005984 hydrogenation reaction Methods 0.000 claims description 5
- 201000010849 intracranial embolism Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 231100000241 scar Toxicity 0.000 claims description 5
- 238000007892 surgical revascularization Methods 0.000 claims description 5
- 206010053159 Organ failure Diseases 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 2
- 102100035792 Kininogen-1 Human genes 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 208000010496 Heart Arrest Diseases 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 270
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 234
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 182
- 239000000243 solution Substances 0.000 description 176
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 140
- 238000005160 1H NMR spectroscopy Methods 0.000 description 120
- 230000002829 reductive effect Effects 0.000 description 108
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 108
- 238000006243 chemical reaction Methods 0.000 description 100
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 85
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 75
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 73
- 239000002904 solvent Substances 0.000 description 60
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 46
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 46
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 45
- 239000008367 deionised water Substances 0.000 description 45
- 229910021641 deionized water Inorganic materials 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 239000007864 aqueous solution Substances 0.000 description 44
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 42
- 239000000047 product Substances 0.000 description 40
- 239000007787 solid Substances 0.000 description 38
- 239000000284 extract Substances 0.000 description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 35
- 239000000741 silica gel Substances 0.000 description 35
- 229910002027 silica gel Inorganic materials 0.000 description 35
- 238000004440 column chromatography Methods 0.000 description 34
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 28
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 27
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 238000010828 elution Methods 0.000 description 23
- 238000004255 ion exchange chromatography Methods 0.000 description 23
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 23
- 235000019341 magnesium sulphate Nutrition 0.000 description 23
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 22
- 238000010898 silica gel chromatography Methods 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 238000010992 reflux Methods 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 238000001704 evaporation Methods 0.000 description 20
- 230000008020 evaporation Effects 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 238000003556 assay Methods 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 239000007832 Na2SO4 Substances 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- 239000008346 aqueous phase Substances 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 238000004809 thin layer chromatography Methods 0.000 description 16
- -1 2-guanidinoethylmercaptosuccinyl Chemical group 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 150000001412 amines Chemical class 0.000 description 15
- 239000012043 crude product Substances 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 239000010410 layer Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000003480 eluent Substances 0.000 description 14
- 230000020764 fibrinolysis Effects 0.000 description 14
- 235000019270 ammonium chloride Nutrition 0.000 description 13
- 239000011259 mixed solution Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- 229910000104 sodium hydride Inorganic materials 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 150000001299 aldehydes Chemical class 0.000 description 11
- 230000015271 coagulation Effects 0.000 description 11
- 238000005345 coagulation Methods 0.000 description 11
- 239000006260 foam Substances 0.000 description 11
- 238000005755 formation reaction Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- 102400000967 Bradykinin Human genes 0.000 description 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 150000001336 alkenes Chemical class 0.000 description 10
- 239000012230 colorless oil Substances 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 239000002480 mineral oil Substances 0.000 description 10
- 235000010446 mineral oil Nutrition 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000012312 sodium hydride Substances 0.000 description 10
- OTDGPKRCQXSTPV-JTQLQIEISA-N (2s)-5-azaniumyl-2-[(1-propylimidazol-4-yl)methyl]pentanoate Chemical compound CCCN1C=NC(C[C@H](CCCN)C(O)=O)=C1 OTDGPKRCQXSTPV-JTQLQIEISA-N 0.000 description 9
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000003456 ion exchange resin Substances 0.000 description 9
- 229920003303 ion-exchange polymer Polymers 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 108090000190 Thrombin Proteins 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 239000002808 molecular sieve Substances 0.000 description 8
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 8
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 7
- 238000005804 alkylation reaction Methods 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 230000035602 clotting Effects 0.000 description 7
- 208000029078 coronary artery disease Diseases 0.000 description 7
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 239000001632 sodium acetate Substances 0.000 description 7
- 235000017281 sodium acetate Nutrition 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 102000003847 Carboxypeptidase B2 Human genes 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 108010085169 Lysine carboxypeptidase Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 229920001429 chelating resin Polymers 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 150000003951 lactams Chemical class 0.000 description 6
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 6
- ACNRTYKOPZDRCO-UHFFFAOYSA-N tert-butyl n-(2-oxoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC=O ACNRTYKOPZDRCO-UHFFFAOYSA-N 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- ULMHMJAEGZPQRY-UHFFFAOYSA-N N-(tert-butoxycarbonyl)piperidin-2-one Chemical compound CC(C)(C)OC(=O)N1CCCCC1=O ULMHMJAEGZPQRY-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 230000010410 reperfusion Effects 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- IXFBXFWVMCKOHZ-NSHDSACASA-N (2s)-5-amino-2-[(1-butylimidazol-4-yl)methyl]pentanoic acid Chemical compound CCCCN1C=NC(C[C@H](CCCN)C(O)=O)=C1 IXFBXFWVMCKOHZ-NSHDSACASA-N 0.000 description 4
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 4
- OTDGPKRCQXSTPV-UHFFFAOYSA-N 5-azaniumyl-2-[(1-propylimidazol-4-yl)methyl]pentanoate Chemical compound CCCN1C=NC(CC(CCCN)C(O)=O)=C1 OTDGPKRCQXSTPV-UHFFFAOYSA-N 0.000 description 4
- APISFIHOBKRZOG-UHFFFAOYSA-N 6-amino-2-[(1-propylimidazol-4-yl)methyl]hexanoic acid Chemical compound CCCN1C=NC(CC(CCCCN)C(O)=O)=C1 APISFIHOBKRZOG-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- 102000013566 Plasminogen Human genes 0.000 description 4
- 108010051456 Plasminogen Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 102000019400 Tissue-type plasminogen activator Human genes 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- RWEVEEORUORBAX-VIFPVBQESA-N methyl (2s)-3-(1h-imidazol-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OC)CC1=CNC=N1 RWEVEEORUORBAX-VIFPVBQESA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 235000019260 propionic acid Nutrition 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 3
- YHBCRXAIIVZWEW-UHFFFAOYSA-N 2-[3-(diaminomethylideneamino)phenyl]-3-sulfanylpropanoic acid Chemical compound NC(=N)NC1=CC=CC(C(CS)C(O)=O)=C1 YHBCRXAIIVZWEW-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 229940121981 Carboxypeptidase inhibitor Drugs 0.000 description 3
- 101710127041 Carboxypeptidase inhibitor Proteins 0.000 description 3
- 102000005367 Carboxypeptidases Human genes 0.000 description 3
- 108010006303 Carboxypeptidases Proteins 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 3
- 108010062466 Enzyme Precursors Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 101710140999 Metallocarboxypeptidase inhibitor Proteins 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 3
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229960001404 quinidine Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JZLQYMHAXPPICX-RXMQYKEDSA-N (2r)-2-chloro-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@H](Cl)CC1=CNC=N1 JZLQYMHAXPPICX-RXMQYKEDSA-N 0.000 description 2
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 2
- LLJMTPSWZYCMHR-NSHDSACASA-N (2s)-2-(2-aminoethylamino)-3-(1-butylimidazol-4-yl)propanoic acid Chemical compound CCCCN1C=NC(C[C@H](NCCN)C(O)=O)=C1 LLJMTPSWZYCMHR-NSHDSACASA-N 0.000 description 2
- UVTMXVBQOPVNHA-JTQLQIEISA-N (2s)-2-(2-aminoethylamino)-3-(1-propylimidazol-4-yl)propanoic acid Chemical compound CCCN1C=NC(C[C@H](NCCN)C(O)=O)=C1 UVTMXVBQOPVNHA-JTQLQIEISA-N 0.000 description 2
- NPKZUKQZSWBBHG-NSHDSACASA-N (2s)-2-(2-aminoethylamino)-3-[1-(1,3-thiazol-5-ylmethyl)imidazol-4-yl]propanoic acid Chemical compound C1=NC(C[C@H](NCCN)C(O)=O)=CN1CC1=CN=CS1 NPKZUKQZSWBBHG-NSHDSACASA-N 0.000 description 2
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108090000087 Carboxypeptidase B Proteins 0.000 description 2
- 102000003670 Carboxypeptidase B Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 206010040860 Skin haemorrhages Diseases 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 102100026966 Thrombomodulin Human genes 0.000 description 2
- 108010079274 Thrombomodulin Proteins 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- DWAYENIPKPKKMV-ILKKLZGPSA-N [(2s)-3-(1h-imidazol-3-ium-4-yl)-1-methoxy-1-oxopropan-2-yl]azanium;dichloride Chemical compound Cl.Cl.COC(=O)[C@@H](N)CC1=CN=CN1 DWAYENIPKPKKMV-ILKKLZGPSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000006254 arylation reaction Methods 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940030980 inova Drugs 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003805 procoagulant Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XJVZHKXGDQXSNT-UHFFFAOYSA-N tert-butyl n-[2-[methoxy(methyl)amino]-2-oxoethyl]carbamate Chemical compound CON(C)C(=O)CNC(=O)OC(C)(C)C XJVZHKXGDQXSNT-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- QJHHZSHQPWRYCL-JLHYYAGUSA-N (2e)-5-[(2-methylpropan-2-yl)oxycarbonylamino]-2-[(1-propylimidazol-4-yl)methylidene]pentanoic acid Chemical compound CCCN1C=NC(\C=C(/CCCNC(=O)OC(C)(C)C)C(O)=O)=C1 QJHHZSHQPWRYCL-JLHYYAGUSA-N 0.000 description 1
- HRGIXOAUBWGTCB-SSDOTTSWSA-N (2r)-2-(2-aminoethylamino)-3-(1h-imidazol-5-yl)propanoic acid Chemical compound NCCN[C@@H](C(O)=O)CC1=CNC=N1 HRGIXOAUBWGTCB-SSDOTTSWSA-N 0.000 description 1
- ITHXTSANOXLYDY-RXMQYKEDSA-N (2r)-2-[(2-bromoacetyl)amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@H](C(O)=O)NC(=O)CBr ITHXTSANOXLYDY-RXMQYKEDSA-N 0.000 description 1
- FCFWEOGTZZPCTO-MRVPVSSYSA-N (2r)-3,6-dimethoxy-2-propan-2-yl-2,5-dihydropyrazine Chemical compound COC1=N[C@H](C(C)C)C(OC)=NC1 FCFWEOGTZZPCTO-MRVPVSSYSA-N 0.000 description 1
- BJQWDKXNACRDDN-SSDOTTSWSA-N (2r)-5-amino-2-(1h-imidazol-5-ylmethyl)pentanoic acid Chemical compound NCCC[C@@H](C(O)=O)CC1=CNC=N1 BJQWDKXNACRDDN-SSDOTTSWSA-N 0.000 description 1
- IXFBXFWVMCKOHZ-LLVKDONJSA-N (2r)-5-amino-2-[(1-butylimidazol-4-yl)methyl]pentanoic acid Chemical compound CCCCN1C=NC(C[C@@H](CCCN)C(O)=O)=C1 IXFBXFWVMCKOHZ-LLVKDONJSA-N 0.000 description 1
- CKGDTHHWMZCQDH-JTQLQIEISA-N (2s)-2-(1,4-diazepan-1-yl)-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)N1CCNCCC1)C1=CNC=N1 CKGDTHHWMZCQDH-JTQLQIEISA-N 0.000 description 1
- RZHAWQYSDSVTHN-AWEZNQCLSA-N (2s)-2-(2-aminoethylamino)-3-(1-benzylimidazol-4-yl)propanoic acid Chemical compound C1=NC(C[C@H](NCCN)C(O)=O)=CN1CC1=CC=CC=C1 RZHAWQYSDSVTHN-AWEZNQCLSA-N 0.000 description 1
- RVUXHJZTETWWDB-VIFPVBQESA-N (2s)-2-(2-aminoethylamino)-3-(1-ethylimidazol-4-yl)propanoic acid Chemical compound CCN1C=NC(C[C@H](NCCN)C(O)=O)=C1 RVUXHJZTETWWDB-VIFPVBQESA-N 0.000 description 1
- ZIGWTNNVVANKME-QMMMGPOBSA-N (2s)-2-(2-aminoethylamino)-3-(1-methylimidazol-4-yl)propanoic acid Chemical compound CN1C=NC(C[C@H](NCCN)C(O)=O)=C1 ZIGWTNNVVANKME-QMMMGPOBSA-N 0.000 description 1
- XZDAXLNUXHTEAZ-LURJTMIESA-N (2s)-2-(2-aminoethylamino)-3-(1h-imidazol-2-yl)propanoic acid Chemical compound NCCN[C@H](C(O)=O)CC1=NC=CN1 XZDAXLNUXHTEAZ-LURJTMIESA-N 0.000 description 1
- HRGIXOAUBWGTCB-ZETCQYMHSA-N (2s)-2-(2-aminoethylamino)-3-(1h-imidazol-5-yl)propanoic acid Chemical compound NCCN[C@H](C(O)=O)CC1=CNC=N1 HRGIXOAUBWGTCB-ZETCQYMHSA-N 0.000 description 1
- UPOWVJPHTYASQZ-QMMMGPOBSA-N (2s)-2-(2-aminoethylamino)-3-[1-(carboxymethyl)imidazol-4-yl]propanoic acid Chemical compound NCCN[C@H](C(O)=O)CC1=CN(CC(O)=O)C=N1 UPOWVJPHTYASQZ-QMMMGPOBSA-N 0.000 description 1
- IYRZGGUIWNGYNV-PYMCNQPYSA-N (2s)-2-[(1-amino-3-phenylpropan-2-yl)amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound N([C@@H](CC=1N=CNC=1)C(O)=O)C(CN)CC1=CC=CC=C1 IYRZGGUIWNGYNV-PYMCNQPYSA-N 0.000 description 1
- HSDUKFOOYACLBO-QMMMGPOBSA-N (2s)-2-[2-aminoethyl(methyl)amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound NCCN(C)[C@H](C(O)=O)CC1=CNC=N1 HSDUKFOOYACLBO-QMMMGPOBSA-N 0.000 description 1
- KCMTVJQUIHHGHR-OOZYFLPDSA-N (2s)-2-[[(2r,3s)-3-aminobutan-2-yl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C[C@H](N)[C@@H](C)N[C@H](C(O)=O)CC1=CNC=N1 KCMTVJQUIHHGHR-OOZYFLPDSA-N 0.000 description 1
- KKIZIPJHNMOLIB-VIFPVBQESA-N (2s)-3-(1h-imidazol-5-yl)-2-piperazin-1-ylpropanoic acid Chemical compound C([C@@H](C(=O)O)N1CCNCC1)C1=CNC=N1 KKIZIPJHNMOLIB-VIFPVBQESA-N 0.000 description 1
- RSBLYDDDDLUCLE-ZDUSSCGKSA-N (2s)-5-[(2-methylpropan-2-yl)oxycarbonylamino]-2-[(1-propylimidazol-4-yl)methyl]pentanoic acid Chemical compound CCCN1C=NC(C[C@H](CCCNC(=O)OC(C)(C)C)C(O)=O)=C1 RSBLYDDDDLUCLE-ZDUSSCGKSA-N 0.000 description 1
- BJQWDKXNACRDDN-ZETCQYMHSA-N (2s)-5-amino-2-(1h-imidazol-5-ylmethyl)pentanoic acid Chemical compound NCCC[C@H](C(O)=O)CC1=CNC=N1 BJQWDKXNACRDDN-ZETCQYMHSA-N 0.000 description 1
- CSUSDXHFQWIDRP-UKTHLTGXSA-N (3e)-1-methyl-3-[[1-(3-methylbutyl)imidazol-4-yl]methylidene]piperidin-2-one Chemical compound CC(C)CCN1C=NC(\C=C/2C(N(C)CCC\2)=O)=C1 CSUSDXHFQWIDRP-UKTHLTGXSA-N 0.000 description 1
- CSUSDXHFQWIDRP-LCYFTJDESA-N (3z)-1-methyl-3-[[1-(3-methylbutyl)imidazol-4-yl]methylidene]piperidin-2-one Chemical compound CC(C)CCN1C=NC(\C=C\2C(N(C)CCC/2)=O)=C1 CSUSDXHFQWIDRP-LCYFTJDESA-N 0.000 description 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- NQOFYFRKWDXGJP-UHFFFAOYSA-N 1,1,2-trimethylguanidine Chemical compound CN=C(N)N(C)C NQOFYFRKWDXGJP-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- ORECNKBJIMKZNX-UHFFFAOYSA-N 1,3-thiazol-3-ium;chloride Chemical compound Cl.C1=CSC=N1 ORECNKBJIMKZNX-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- DHGMDHQNUNRMIN-UHFFFAOYSA-N 1-benzylpyrrolidin-3-one Chemical compound C1C(=O)CCN1CC1=CC=CC=C1 DHGMDHQNUNRMIN-UHFFFAOYSA-N 0.000 description 1
- YXZFFTJAHVMMLF-UHFFFAOYSA-N 1-bromo-3-methylbutane Chemical compound CC(C)CCBr YXZFFTJAHVMMLF-UHFFFAOYSA-N 0.000 description 1
- NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- KMOHCSSRGNKKLF-UHFFFAOYSA-N 1-methyl-3-[[1-(3-methylbutyl)imidazol-4-yl]methyl]piperidin-2-one Chemical compound CC(C)CCN1C=NC(CC2C(N(C)CCC2)=O)=C1 KMOHCSSRGNKKLF-UHFFFAOYSA-N 0.000 description 1
- GGYVTHJIUNGKFZ-UHFFFAOYSA-N 1-methylpiperidin-2-one Chemical compound CN1CCCCC1=O GGYVTHJIUNGKFZ-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- XZDAXLNUXHTEAZ-UHFFFAOYSA-N 2-(2-aminoethylamino)-3-(1h-imidazol-2-yl)propanoic acid Chemical compound NCCNC(C(O)=O)CC1=NC=CN1 XZDAXLNUXHTEAZ-UHFFFAOYSA-N 0.000 description 1
- SAXTXIDZMKZQMV-UHFFFAOYSA-N 2-(2-bromoethyl)pyridin-1-ium;bromide Chemical compound Br.BrCCC1=CC=CC=N1 SAXTXIDZMKZQMV-UHFFFAOYSA-N 0.000 description 1
- NFBNRSPJIMVFNB-UHFFFAOYSA-N 2-[[2-(chloromethyl)imidazol-1-yl]methoxy]ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCN1C=CN=C1CCl NFBNRSPJIMVFNB-UHFFFAOYSA-N 0.000 description 1
- ISKXXOHISPGNSB-NVXWUHKLSA-N 2-[[2-[[(2r,5r)-3,6-dimethoxy-5-propan-2-yl-2,5-dihydropyrazin-2-yl]methyl]imidazol-1-yl]methoxy]ethyl-trimethylsilane Chemical compound COC1=N[C@H](C(C)C)C(OC)=N[C@@H]1CC1=NC=CN1COCC[Si](C)(C)C ISKXXOHISPGNSB-NVXWUHKLSA-N 0.000 description 1
- SRDNJJJAHZNVBC-UHFFFAOYSA-N 2-bromo-n-[4-(diaminomethylideneamino)butyl]acetamide Chemical compound NC(=N)NCCCCNC(=O)CBr SRDNJJJAHZNVBC-UHFFFAOYSA-N 0.000 description 1
- LBVZINOLAFTARU-UHFFFAOYSA-N 2-bromo-n-methylacetamide Chemical compound CNC(=O)CBr LBVZINOLAFTARU-UHFFFAOYSA-N 0.000 description 1
- DOGFOANXOUKFEC-UHFFFAOYSA-N 2-bromopentanal Chemical compound CCCC(Br)C=O DOGFOANXOUKFEC-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- PTKCEDPIGMNZSL-UHFFFAOYSA-N 3-(tritylamino)propan-1-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(NCCCO)C1=CC=CC=C1 PTKCEDPIGMNZSL-UHFFFAOYSA-N 0.000 description 1
- UPOJJKSHDPYSQT-UHFFFAOYSA-N 3-[hydroxy-[1-(3-methylbutyl)imidazol-4-yl]methyl]-1-methylpiperidin-2-one Chemical compound CC(C)CCN1C=NC(C(O)C2C(N(C)CCC2)=O)=C1 UPOJJKSHDPYSQT-UHFFFAOYSA-N 0.000 description 1
- NLFQSUHOYMIIQI-UHFFFAOYSA-N 3-bromo-n-tritylpropan-1-amine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(NCCCBr)C1=CC=CC=C1 NLFQSUHOYMIIQI-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- OUTUZEBQXNEVGY-UHFFFAOYSA-N 5,5-diethyl-1,3-diazinane-2,4,6-trione;4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O.O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 OUTUZEBQXNEVGY-UHFFFAOYSA-N 0.000 description 1
- PIOYVIQXEZHHET-UHFFFAOYSA-N 5-(methylamino)-2-[[1-(3-methylbutyl)imidazol-4-yl]methyl]pentanoic acid Chemical compound CNCCCC(C(O)=O)CC1=CN(CCC(C)C)C=N1 PIOYVIQXEZHHET-UHFFFAOYSA-N 0.000 description 1
- RSBLYDDDDLUCLE-UHFFFAOYSA-N 5-[(2-methylpropan-2-yl)oxycarbonylamino]-2-[(1-propylimidazol-4-yl)methyl]pentanoic acid Chemical compound CCCN1C=NC(CC(CCCNC(=O)OC(C)(C)C)C(O)=O)=C1 RSBLYDDDDLUCLE-UHFFFAOYSA-N 0.000 description 1
- BJQWDKXNACRDDN-UHFFFAOYSA-N 5-amino-2-(1h-imidazol-5-ylmethyl)pentanoic acid Chemical compound NCCCC(C(O)=O)CC1=CNC=N1 BJQWDKXNACRDDN-UHFFFAOYSA-N 0.000 description 1
- BSUKBOUHTXROIW-UHFFFAOYSA-N 5-amino-2-[(1-phenylimidazol-4-yl)methyl]pentanoic acid Chemical compound C1=NC(CC(CCCN)C(O)=O)=CN1C1=CC=CC=C1 BSUKBOUHTXROIW-UHFFFAOYSA-N 0.000 description 1
- NFPDLPIBAQFOJU-UHFFFAOYSA-N 5-amino-2-[(5-propyl-1h-imidazol-2-yl)methyl]pentanoic acid Chemical compound CCCC1=CNC(CC(CCCN)C(O)=O)=N1 NFPDLPIBAQFOJU-UHFFFAOYSA-N 0.000 description 1
- WXWYBESKOJOXPF-UHFFFAOYSA-N 5-amino-2-[[1-(3-methylbutyl)imidazol-4-yl]methyl]pentanoic acid Chemical compound CC(C)CCN1C=NC(CC(CCCN)C(O)=O)=C1 WXWYBESKOJOXPF-UHFFFAOYSA-N 0.000 description 1
- HPSJFXKHFLNPQM-UHFFFAOYSA-N 5-propyl-1h-imidazole Chemical compound CCCC1=CNC=N1 HPSJFXKHFLNPQM-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- UYRZZHXGQRYADV-UHFFFAOYSA-N 6-[(2-methylpropan-2-yl)oxycarbonylamino]-2-[(1-propylimidazol-4-yl)methyl]hexanoic acid Chemical compound CCCN1C=NC(CC(CCCCNC(=O)OC(C)(C)C)C(O)=O)=C1 UYRZZHXGQRYADV-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000005657 Antithrombin III deficiency Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 101000946522 Bos taurus Carboxypeptidase B Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WTWHKYAHEHUQNG-UHFFFAOYSA-N CC1=CC(=C(C=C1)S(=O)(=O)O)C(C)COC Chemical compound CC1=CC(=C(C=C1)S(=O)(=O)O)C(C)COC WTWHKYAHEHUQNG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102100035024 Carboxypeptidase B Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- YKMCGJHMYUQXEV-LTCKWSDVSA-N Cl.Cl.C1=NC(C[C@H](N)C(=O)OC)=CN1C1=CC=CC=C1 Chemical compound Cl.Cl.C1=NC(C[C@H](N)C(=O)OC)=CN1C1=CC=CC=C1 YKMCGJHMYUQXEV-LTCKWSDVSA-N 0.000 description 1
- XVCHPEPHTPUMCU-XRIOVQLTSA-N Cl.Cl.C1=NC(C[C@H](N)C(=O)OC)=CN1CC1=CN=CS1 Chemical compound Cl.Cl.C1=NC(C[C@H](N)C(=O)OC)=CN1CC1=CN=CS1 XVCHPEPHTPUMCU-XRIOVQLTSA-N 0.000 description 1
- FAASKHNWTYKWQU-GXKRWWSZSA-N Cl.Cl.C1=NC(C[C@H](N)C(=O)OC)=CN1CCC1=CC=CC=N1 Chemical compound Cl.Cl.C1=NC(C[C@H](N)C(=O)OC)=CN1CCC1=CC=CC=N1 FAASKHNWTYKWQU-GXKRWWSZSA-N 0.000 description 1
- PLULINGRYYMDLH-WWPIYYJJSA-N Cl.Cl.COC(=O)[C@@H](N)CC1=CN(CCCC(F)(F)F)C=N1 Chemical compound Cl.Cl.COC(=O)[C@@H](N)CC1=CN(CCCC(F)(F)F)C=N1 PLULINGRYYMDLH-WWPIYYJJSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
- 229930195721 D-histidine Natural products 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 229940122564 Factor X inhibitor Drugs 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 101000946524 Homo sapiens Carboxypeptidase B Proteins 0.000 description 1
- 101000946518 Homo sapiens Carboxypeptidase B2 Proteins 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- BXRMEWOQUXOLDH-LURJTMIESA-N L-Histidine methyl ester Chemical compound COC(=O)[C@@H](N)CC1=CN=CN1 BXRMEWOQUXOLDH-LURJTMIESA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 201000005660 Protein C Deficiency Diseases 0.000 description 1
- 206010051292 Protein S Deficiency Diseases 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZQKHRAXLCGDJDL-UHFFFAOYSA-N [1-(2-trimethylsilylethoxymethyl)imidazol-2-yl]methanol Chemical compound C[Si](C)(C)CCOCN1C=CN=C1CO ZQKHRAXLCGDJDL-UHFFFAOYSA-N 0.000 description 1
- UINABNFYKSFGNQ-BTQNPOSSSA-M [Li+].CCCN1C=NC(C[C@@H](CCCNC(=O)OC(C)(C)C)C([O-])=O)=C1 Chemical compound [Li+].CCCN1C=NC(C[C@@H](CCCNC(=O)OC(C)(C)C)C([O-])=O)=C1 UINABNFYKSFGNQ-BTQNPOSSSA-M 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- WQILMAABTBCPJO-MUUNZHRXSA-N ethyl (2r)-2-[(1-butylimidazol-4-yl)methyl]-5-(tritylamino)pentanoate Chemical compound CCCCN1C=NC(C[C@@H](CCCNC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C(=O)OCC)=C1 WQILMAABTBCPJO-MUUNZHRXSA-N 0.000 description 1
- GKDQSXDRXPVJNH-SSEXGKCCSA-N ethyl (2r)-2-[[1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methyl]-5-(tritylamino)pentanoate Chemical compound C([C@@H](C(=O)OCC)CC=1N=CN(COCC[Si](C)(C)C)C=1)CCNC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 GKDQSXDRXPVJNH-SSEXGKCCSA-N 0.000 description 1
- WQILMAABTBCPJO-NDEPHWFRSA-N ethyl (2s)-2-[(1-butylimidazol-4-yl)methyl]-5-(tritylamino)pentanoate Chemical compound CCCCN1C=NC(C[C@H](CCCNC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C(=O)OCC)=C1 WQILMAABTBCPJO-NDEPHWFRSA-N 0.000 description 1
- GKDQSXDRXPVJNH-PMERELPUSA-N ethyl (2s)-2-[[1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methyl]-5-(tritylamino)pentanoate Chemical compound C([C@H](C(=O)OCC)CC=1N=CN(COCC[Si](C)(C)C)C=1)CCNC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 GKDQSXDRXPVJNH-PMERELPUSA-N 0.000 description 1
- WQILMAABTBCPJO-UHFFFAOYSA-N ethyl 2-[(1-butylimidazol-4-yl)methyl]-5-(tritylamino)pentanoate Chemical compound CCCCN1C=NC(CC(CCCNC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C(=O)OCC)=C1 WQILMAABTBCPJO-UHFFFAOYSA-N 0.000 description 1
- QJQOYGFHOFMLBS-UHFFFAOYSA-N ethyl 2-[(1-propylimidazol-4-yl)methyl]-5-(tritylamino)pentanoate Chemical compound CCCN1C=NC(CC(CCCNC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C(=O)OCC)=C1 QJQOYGFHOFMLBS-UHFFFAOYSA-N 0.000 description 1
- GKDQSXDRXPVJNH-UHFFFAOYSA-N ethyl 2-[[1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methyl]-5-(tritylamino)pentanoate Chemical compound C=1N(COCC[Si](C)(C)C)C=NC=1CC(C(=O)OCC)CCCNC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 GKDQSXDRXPVJNH-UHFFFAOYSA-N 0.000 description 1
- VCVCPNUDDWDCSE-UHFFFAOYSA-N ethyl 2-diethoxyphosphoryl-5-(tritylamino)pentanoate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(NCCCC(C(=O)OCC)P(=O)(OCC)OCC)C1=CC=CC=C1 VCVCPNUDDWDCSE-UHFFFAOYSA-N 0.000 description 1
- MJEHYVVLLAXGND-UHFFFAOYSA-N ethyl 6-[benzyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-2-diethoxyphosphorylhexanoate Chemical compound CCOC(=O)C(P(=O)(OCC)OCC)CCCCN(C(=O)OC(C)(C)C)CC1=CC=CC=C1 MJEHYVVLLAXGND-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229940049370 fibrinolysis inhibitor Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000033666 hereditary antithrombin deficiency Diseases 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- BXRMEWOQUXOLDH-ZCFIWIBFSA-N methyl (2r)-2-amino-3-(1h-imidazol-5-yl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CN=CN1 BXRMEWOQUXOLDH-ZCFIWIBFSA-N 0.000 description 1
- JIPJJONLBKXGDE-ZCFIWIBFSA-N methyl (2r)-2-chloro-3-(1h-imidazol-5-yl)propanoate Chemical compound COC(=O)[C@H](Cl)CC1=CNC=N1 JIPJJONLBKXGDE-ZCFIWIBFSA-N 0.000 description 1
- GHGYFVAFDSNOPO-LLVKDONJSA-N methyl (2r)-3-(1h-imidazol-5-yl)-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylamino]propanoate Chemical compound CC(C)(C)OC(=O)NCCN[C@@H](C(=O)OC)CC1=CNC=N1 GHGYFVAFDSNOPO-LLVKDONJSA-N 0.000 description 1
- LUJUHTBGPNIQKS-HNNXBMFYSA-N methyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(1-phenylimidazol-4-yl)propanoate Chemical compound C1=NC(C[C@@H](C(=O)OC)NC(=O)OC(C)(C)C)=CN1C1=CC=CC=C1 LUJUHTBGPNIQKS-HNNXBMFYSA-N 0.000 description 1
- XPRDARMEWCKIDP-ZDUSSCGKSA-N methyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[1-(1,3-thiazol-5-ylmethyl)imidazol-4-yl]propanoate Chemical compound C1=NC(C[C@@H](C(=O)OC)NC(=O)OC(C)(C)C)=CN1CC1=CN=CS1 XPRDARMEWCKIDP-ZDUSSCGKSA-N 0.000 description 1
- ULASEBLRBGSPJG-INIZCTEOSA-N methyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[1-(2-pyridin-2-ylethyl)imidazol-4-yl]propanoate Chemical compound C1=NC(C[C@@H](C(=O)OC)NC(=O)OC(C)(C)C)=CN1CCC1=CC=CC=N1 ULASEBLRBGSPJG-INIZCTEOSA-N 0.000 description 1
- RAHBECXQDSXLEI-LBPRGKRZSA-N methyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[1-(4,4,4-trifluorobutyl)imidazol-4-yl]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OC)CC1=CN(CCCC(F)(F)F)C=N1 RAHBECXQDSXLEI-LBPRGKRZSA-N 0.000 description 1
- UZXAQVYNKQSTLD-INIZCTEOSA-N methyl (2s)-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylamino]-3-[1-(2-trimethylsilylethoxymethyl)imidazol-2-yl]propanoate Chemical compound CC(C)(C)OC(=O)NCCN[C@H](C(=O)OC)CC1=NC=CN1COCC[Si](C)(C)C UZXAQVYNKQSTLD-INIZCTEOSA-N 0.000 description 1
- WJYYUKAXIYOKFU-DHUJRADRSA-N methyl (2s)-2-[4-(4-methylphenyl)sulfonylpiperazin-1-yl]-3-(1-tritylimidazol-4-yl)propanoate Chemical compound C([C@@H](C(=O)OC)N1CCN(CC1)S(=O)(=O)C=1C=CC(C)=CC=1)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WJYYUKAXIYOKFU-DHUJRADRSA-N 0.000 description 1
- SPYVYWCBBVEEBH-DEOSSOPVSA-N methyl (2s)-2-amino-3-(1-tritylimidazol-4-yl)propanoate Chemical compound C1=NC(C[C@H](N)C(=O)OC)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 SPYVYWCBBVEEBH-DEOSSOPVSA-N 0.000 description 1
- VELWPGLLUYCYAK-NSHDSACASA-N methyl (2s)-2-amino-3-[1-(2-trimethylsilylethoxymethyl)imidazol-2-yl]propanoate Chemical compound COC(=O)[C@@H](N)CC1=NC=CN1COCC[Si](C)(C)C VELWPGLLUYCYAK-NSHDSACASA-N 0.000 description 1
- YCJGEYAXQHNYQL-LBPRGKRZSA-N methyl (2s)-3-(1-methylimidazol-4-yl)-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylamino]propanoate Chemical compound CC(C)(C)OC(=O)NCCN[C@H](C(=O)OC)CC1=CN(C)C=N1 YCJGEYAXQHNYQL-LBPRGKRZSA-N 0.000 description 1
- GHGYFVAFDSNOPO-NSHDSACASA-N methyl (2s)-3-(1h-imidazol-5-yl)-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylamino]propanoate Chemical compound CC(C)(C)OC(=O)NCCN[C@H](C(=O)OC)CC1=CNC=N1 GHGYFVAFDSNOPO-NSHDSACASA-N 0.000 description 1
- JIHSFLXGQZKPKO-LBPRGKRZSA-N methyl (2s)-3-(1h-imidazol-5-yl)-2-[methyl-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]amino]propanoate Chemical compound CC(C)(C)OC(=O)NCCN(C)[C@H](C(=O)OC)CC1=CNC=N1 JIHSFLXGQZKPKO-LBPRGKRZSA-N 0.000 description 1
- FAGZFTCHOFZRHX-JTQLQIEISA-N methyl (2s)-3-(1h-imidazol-5-yl)-2-piperazin-1-ylpropanoate Chemical compound C([C@@H](C(=O)OC)N1CCNCC1)C1=CNC=N1 FAGZFTCHOFZRHX-JTQLQIEISA-N 0.000 description 1
- WCRFAUOLNAZNCA-MLWJPKLSSA-N methyl (2s)-3-imidazolidin-4-yl-2-(methylamino)propanoate Chemical compound COC(=O)[C@@H](NC)CC1CNCN1 WCRFAUOLNAZNCA-MLWJPKLSSA-N 0.000 description 1
- PATUMPKDMWCFOE-ZOWNYOTGSA-N methyl (7s)-2-[2-(methylamino)-2-oxoethyl]-6-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-5-oxo-7,8-dihydroimidazo[1,5-c]pyrimidin-2-ium-7-carboxylate;bromide Chemical compound [Br-].C1[C@@H](C(=O)OC)N(CCNC(=O)OC(C)(C)C)C(=O)N2C=[N+](CC(=O)NC)C=C21 PATUMPKDMWCFOE-ZOWNYOTGSA-N 0.000 description 1
- TYCPPLYXGWDNDY-FERBBOLQSA-N methyl (7s)-2-benzyl-6-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-5-oxo-7,8-dihydroimidazo[1,5-c]pyrimidin-2-ium-7-carboxylate;bromide Chemical compound [Br-].C([C@H](N(C(=O)N1C=2)CCNC(=O)OC(C)(C)C)C(=O)OC)C1=C[N+]=2CC1=CC=CC=C1 TYCPPLYXGWDNDY-FERBBOLQSA-N 0.000 description 1
- ZSZBITHROHSMRG-ZOWNYOTGSA-N methyl (7s)-2-ethyl-6-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-5-oxo-7,8-dihydroimidazo[1,5-c]pyrimidin-2-ium-7-carboxylate;iodide Chemical compound [I-].C1[C@@H](C(=O)OC)N(CCNC(=O)OC(C)(C)C)C(=O)N2C=[N+](CC)C=C21 ZSZBITHROHSMRG-ZOWNYOTGSA-N 0.000 description 1
- YCWZYLFRXDRHRP-NSHDSACASA-N methyl (7s)-6-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-5-oxo-7,8-dihydroimidazo[1,5-c]pyrimidine-7-carboxylate Chemical compound O=C1N(CCNC(=O)OC(C)(C)C)[C@H](C(=O)OC)CC2=CN=CN21 YCWZYLFRXDRHRP-NSHDSACASA-N 0.000 description 1
- OQZHDZZHFRRIMH-XFXZXTDPSA-N methyl (z)-3-(1h-imidazol-2-yl)-2-(phenylmethoxycarbonylamino)prop-2-enoate Chemical compound N=1C=CNC=1/C=C(C(=O)OC)\NC(=O)OCC1=CC=CC=C1 OQZHDZZHFRRIMH-XFXZXTDPSA-N 0.000 description 1
- DTIRGLDETVDPOT-UHFFFAOYSA-N methyl 2-amino-3-(1h-imidazol-2-yl)propanoate Chemical compound COC(=O)C(N)CC1=NC=CN1 DTIRGLDETVDPOT-UHFFFAOYSA-N 0.000 description 1
- JDMYAOGIHRVEMR-UHFFFAOYSA-N methyl 3-(1h-imidazol-2-yl)-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylamino]propanoate Chemical compound CC(C)(C)OC(=O)NCCNC(C(=O)OC)CC1=NC=CN1 JDMYAOGIHRVEMR-UHFFFAOYSA-N 0.000 description 1
- VLZKPLZUZGWKOT-UHFFFAOYSA-N methyl 3-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)propanoate Chemical compound COP(=O)(OC)CC(C(=O)OC)NC(=O)OCC1=CC=CC=C1 VLZKPLZUZGWKOT-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PTVBBIMKLOMGSY-UHFFFAOYSA-N n,n-bis(2-chloroethyl)-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N(CCCl)CCCl)C=C1 PTVBBIMKLOMGSY-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000000711 polarimetry Methods 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- OFGAISUMOYIUTF-UHFFFAOYSA-M sodium;6-[benzyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-2-[(1-propylimidazol-4-yl)methyl]hexanoate Chemical compound [Na+].CCCN1C=NC(CC(CCCCN(CC=2C=CC=CC=2)C(=O)OC(C)(C)C)C([O-])=O)=C1 OFGAISUMOYIUTF-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- PGYYPXUDDSFUFW-JLHYYAGUSA-N tert-butyl (3e)-2-oxo-3-[(1-propylimidazol-4-yl)methylidene]piperidine-1-carboxylate Chemical compound CCCN1C=NC(\C=C/2C(N(C(=O)OC(C)(C)C)CCC\2)=O)=C1 PGYYPXUDDSFUFW-JLHYYAGUSA-N 0.000 description 1
- JAOUZLVHDVSQQI-YYDJUVGSSA-N tert-butyl (3e)-2-oxo-3-[(1-tritylimidazol-4-yl)methylidene]piperidine-1-carboxylate Chemical compound O=C1N(C(=O)OC(C)(C)C)CCC\C1=C/C1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 JAOUZLVHDVSQQI-YYDJUVGSSA-N 0.000 description 1
- XFHQRFBUAKNJJG-RVDMUPIBSA-N tert-butyl (3e)-3-[[1-(3-methylbutyl)imidazol-4-yl]methylidene]-2-oxopiperidine-1-carboxylate Chemical compound CC(C)CCN1C=NC(\C=C/2C(N(C(=O)OC(C)(C)C)CCC\2)=O)=C1 XFHQRFBUAKNJJG-RVDMUPIBSA-N 0.000 description 1
- WGCSLWNGKNXCMO-CYBMUJFWSA-N tert-butyl (3r)-2-oxo-3-[(1-propylimidazol-4-yl)methyl]piperidine-1-carboxylate Chemical compound CCCN1C=NC(C[C@@H]2C(N(C(=O)OC(C)(C)C)CCC2)=O)=C1 WGCSLWNGKNXCMO-CYBMUJFWSA-N 0.000 description 1
- WGCSLWNGKNXCMO-ZDUSSCGKSA-N tert-butyl (3s)-2-oxo-3-[(1-propylimidazol-4-yl)methyl]piperidine-1-carboxylate Chemical compound CCCN1C=NC(C[C@H]2C(N(C(=O)OC(C)(C)C)CCC2)=O)=C1 WGCSLWNGKNXCMO-ZDUSSCGKSA-N 0.000 description 1
- JAOUZLVHDVSQQI-LVWGJNHUSA-N tert-butyl (3z)-2-oxo-3-[(1-tritylimidazol-4-yl)methylidene]piperidine-1-carboxylate Chemical compound O=C1N(C(=O)OC(C)(C)C)CCC\C1=C\C1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 JAOUZLVHDVSQQI-LVWGJNHUSA-N 0.000 description 1
- BOOOZULPXNJWTA-UHFFFAOYSA-N tert-butyl 2-oxo-3-[(1-phenylimidazol-4-yl)methyl]piperidine-1-carboxylate Chemical compound O=C1N(C(=O)OC(C)(C)C)CCCC1CC1=CN(C=2C=CC=CC=2)C=N1 BOOOZULPXNJWTA-UHFFFAOYSA-N 0.000 description 1
- VYVNUWYLGKAJMM-UHFFFAOYSA-N tert-butyl 2-oxo-3-[[4-propyl-1-(2-trimethylsilylethoxymethyl)imidazol-2-yl]methyl]piperidine-1-carboxylate Chemical compound CCCC1=CN(COCC[Si](C)(C)C)C(CC2C(N(C(=O)OC(C)(C)C)CCC2)=O)=N1 VYVNUWYLGKAJMM-UHFFFAOYSA-N 0.000 description 1
- BNUHGKMODGPPDV-UHFFFAOYSA-N tert-butyl 3-(1h-imidazol-5-ylmethyl)-2-oxopiperidine-1-carboxylate Chemical compound O=C1N(C(=O)OC(C)(C)C)CCCC1CC1=CNC=N1 BNUHGKMODGPPDV-UHFFFAOYSA-N 0.000 description 1
- WQIPIFTWSQKVPZ-UHFFFAOYSA-N tert-butyl 3-[[1-(3-methylbutyl)imidazol-4-yl]methyl]-2-oxopiperidine-1-carboxylate Chemical compound CC(C)CCN1C=NC(CC2C(N(C(=O)OC(C)(C)C)CCC2)=O)=C1 WQIPIFTWSQKVPZ-UHFFFAOYSA-N 0.000 description 1
- YMPBAJJEOMXWSZ-UHFFFAOYSA-N tert-butyl 3-[hydroxy-(1-propylimidazol-4-yl)methyl]-2-oxopiperidine-1-carboxylate Chemical compound CCCN1C=NC(C(O)C2C(N(C(=O)OC(C)(C)C)CCC2)=O)=C1 YMPBAJJEOMXWSZ-UHFFFAOYSA-N 0.000 description 1
- SRPFEPWIXYNJHV-UHFFFAOYSA-N tert-butyl 3-[hydroxy-(1-tritylimidazol-4-yl)methyl]-2-oxopiperidine-1-carboxylate Chemical compound O=C1N(C(=O)OC(C)(C)C)CCCC1C(O)C1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 SRPFEPWIXYNJHV-UHFFFAOYSA-N 0.000 description 1
- RIXBYBZSZYTEJS-UHFFFAOYSA-N tert-butyl 3-[hydroxy-[1-(3-methylbutyl)imidazol-4-yl]methyl]-2-oxopiperidine-1-carboxylate Chemical compound CC(C)CCN1C=NC(C(O)C2C(N(C(=O)OC(C)(C)C)CCC2)=O)=C1 RIXBYBZSZYTEJS-UHFFFAOYSA-N 0.000 description 1
- ZXEPSVDICKINTE-UHFFFAOYSA-N tert-butyl n-(2-oxobutyl)carbamate Chemical compound CCC(=O)CNC(=O)OC(C)(C)C ZXEPSVDICKINTE-UHFFFAOYSA-N 0.000 description 1
- PWQIGBOSLQHOBT-ZETCQYMHSA-N tert-butyl n-[(2s)-1-[methoxy(methyl)amino]-1-oxopropan-2-yl]carbamate Chemical compound CON(C)C(=O)[C@H](C)NC(=O)OC(C)(C)C PWQIGBOSLQHOBT-ZETCQYMHSA-N 0.000 description 1
- XODUGXDTYDHWBN-UHFFFAOYSA-N tert-butyl n-benzyl-n-(4-iodobutyl)carbamate Chemical compound ICCCCN(C(=O)OC(C)(C)C)CC1=CC=CC=C1 XODUGXDTYDHWBN-UHFFFAOYSA-N 0.000 description 1
- FWOBBEOKTITUHK-UHFFFAOYSA-N tert-butyl n-benzylcarbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC=C1 FWOBBEOKTITUHK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0020346A GB0020346D0 (en) | 2000-08-17 | 2000-08-17 | Pharmaceuticals |
GB0027409A GB0027409D0 (en) | 2000-11-09 | 2000-11-09 | Pharmaceuticals |
GB0029556A GB0029556D0 (en) | 2000-12-04 | 2000-12-04 | Pharmaceuticals |
PCT/IB2001/001425 WO2002014285A1 (en) | 2000-08-17 | 2001-08-08 | Substituted imidazoles as tafia inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20030103A2 true HRP20030103A2 (en) | 2003-04-30 |
Family
ID=27255849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030103A HRP20030103A2 (en) | 2000-08-17 | 2003-02-13 | Substituted imidazoles as tafia inhibitors |
Country Status (38)
Country | Link |
---|---|
EP (1) | EP1311488B1 (zh) |
JP (2) | JP4119746B2 (zh) |
KR (1) | KR20030022412A (zh) |
CN (1) | CN1443173A (zh) |
AP (1) | AP1375A (zh) |
AR (1) | AR035580A1 (zh) |
AT (1) | ATE447557T1 (zh) |
AU (1) | AU2001276605A1 (zh) |
BG (1) | BG107330A (zh) |
BR (1) | BR0113289A (zh) |
CA (1) | CA2419633C (zh) |
CY (1) | CY1109693T1 (zh) |
CZ (1) | CZ2003388A3 (zh) |
DE (1) | DE60140368D1 (zh) |
DK (1) | DK1311488T3 (zh) |
DO (1) | DOP2001000233A (zh) |
EA (1) | EA005532B1 (zh) |
EE (1) | EE200300070A (zh) |
ES (1) | ES2334101T3 (zh) |
HR (1) | HRP20030103A2 (zh) |
HU (1) | HUP0303763A3 (zh) |
IL (1) | IL153225A0 (zh) |
IS (1) | IS6638A (zh) |
MA (1) | MA26940A1 (zh) |
MX (1) | MXPA03001425A (zh) |
NO (1) | NO20030706L (zh) |
NZ (1) | NZ522823A (zh) |
OA (1) | OA12362A (zh) |
PA (1) | PA8525401A1 (zh) |
PE (1) | PE20020352A1 (zh) |
PL (1) | PL361054A1 (zh) |
PT (1) | PT1311488E (zh) |
SI (1) | SI1311488T1 (zh) |
SK (1) | SK1732003A3 (zh) |
SV (1) | SV2002000602A (zh) |
TN (1) | TNSN01126A1 (zh) |
UY (1) | UY26889A1 (zh) |
WO (1) | WO2002014285A1 (zh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0103272D0 (sv) | 2001-09-28 | 2001-09-28 | Astrazeneca Ab | Chemical compounds |
EP1467731A1 (en) * | 2002-01-22 | 2004-10-20 | Pfizer Limited | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
JP2005516972A (ja) * | 2002-01-22 | 2005-06-09 | ファイザー・インク | 血栓疾患の治療のためのtafi−a阻害剤として使用される3−(イミダゾリル)−2−アミノプロピオン酸 |
US6713496B2 (en) | 2002-01-22 | 2004-03-30 | Pfizer Inc | 3-(imidazolyl)-2-alkoxypropanoic acids |
CA2524222C (en) | 2003-04-29 | 2012-02-07 | Roger Alberto | N.epsilon. and/or n.alpha. derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [m(oh2)3(co)3]+ by fac coordination |
SE0302853D0 (sv) * | 2003-10-29 | 2003-10-29 | Astrazeneca Ab | Chemical compounds |
EP2338490A3 (en) * | 2003-11-03 | 2012-06-06 | Probiodrug AG | Combinations useful for the treatment of neuronal disorders |
WO2005051384A1 (en) * | 2003-11-25 | 2005-06-09 | Pfizer Limited | Stabilised pharmaceutical compositions |
CA2604912A1 (en) * | 2005-04-18 | 2006-10-26 | Bayer Schering Pharma Aktiengesellschaft | Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci |
DE102005049385A1 (de) * | 2005-10-15 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Imidazolderivate als Inhibitoren von TAFIa |
KR20090087044A (ko) * | 2006-12-06 | 2009-08-14 | 사노피-아벤티스 | TAFIa 억제제로서의 요소 및 설파미드 유도체 |
EP2262783A2 (en) * | 2008-02-21 | 2010-12-22 | Sanofi-Aventis | Covalently binding imaging probes |
CA2741783A1 (en) * | 2008-10-29 | 2010-05-06 | Taisho Pharmaceutical Co., Ltd. | Compounds having tafia inhibitory activity |
FR2947266B1 (fr) * | 2009-06-26 | 2011-06-17 | Servier Lab | Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
PL2548871T3 (pl) | 2010-03-18 | 2017-12-29 | Daiichi Sankyo Company, Limited | Pochodne imidazolu podstawionego cykloalkilem |
JP5778133B2 (ja) * | 2010-03-18 | 2015-09-16 | 第一三共株式会社 | シクロプロパンカルボン酸誘導体 |
EP3569636A1 (en) * | 2011-05-17 | 2019-11-20 | Joint Stock Company "Pharmasyntez" | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process |
PL2734508T3 (pl) * | 2011-07-22 | 2018-08-31 | Cambrex Karlskoga Ab | Nowe sposoby wytwarzania 4-podstawionych imidazoli |
WO2013039202A1 (ja) * | 2011-09-15 | 2013-03-21 | 第一三共株式会社 | 新規アクリル酸誘導体 |
US9834527B2 (en) | 2013-06-10 | 2017-12-05 | Sanofi | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals |
US10399958B2 (en) | 2015-10-07 | 2019-09-03 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
FR3046793B1 (fr) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2017170460A1 (ja) * | 2016-03-29 | 2017-10-05 | 第一三共株式会社 | 炎症性腸疾患治療剤 |
US11358954B2 (en) | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6163661A (ja) * | 1984-09-05 | 1986-04-01 | Microbial Chem Res Found | ヒスタジン関連化合物 |
US5993815A (en) * | 1996-11-08 | 1999-11-30 | University Of Vermont | Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI) |
SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
-
2001
- 2001-08-08 JP JP2002519428A patent/JP4119746B2/ja not_active Expired - Fee Related
- 2001-08-08 KR KR10-2003-7002279A patent/KR20030022412A/ko not_active Application Discontinuation
- 2001-08-08 AT AT01954264T patent/ATE447557T1/de active
- 2001-08-08 BR BR0113289-0A patent/BR0113289A/pt not_active Application Discontinuation
- 2001-08-08 SK SK173-2003A patent/SK1732003A3/sk unknown
- 2001-08-08 MX MXPA03001425A patent/MXPA03001425A/es active IP Right Grant
- 2001-08-08 PT PT01954264T patent/PT1311488E/pt unknown
- 2001-08-08 WO PCT/IB2001/001425 patent/WO2002014285A1/en not_active Application Discontinuation
- 2001-08-08 EP EP01954264A patent/EP1311488B1/en not_active Expired - Lifetime
- 2001-08-08 IL IL15322501A patent/IL153225A0/xx unknown
- 2001-08-08 DK DK01954264T patent/DK1311488T3/da active
- 2001-08-08 CZ CZ2003388A patent/CZ2003388A3/cs unknown
- 2001-08-08 CN CN01813131A patent/CN1443173A/zh active Pending
- 2001-08-08 AU AU2001276605A patent/AU2001276605A1/en not_active Abandoned
- 2001-08-08 DE DE60140368T patent/DE60140368D1/de not_active Expired - Lifetime
- 2001-08-08 NZ NZ522823A patent/NZ522823A/en unknown
- 2001-08-08 OA OA1200300039A patent/OA12362A/fr unknown
- 2001-08-08 EA EA200201239A patent/EA005532B1/ru not_active IP Right Cessation
- 2001-08-08 PL PL36105401A patent/PL361054A1/xx not_active Application Discontinuation
- 2001-08-08 SI SI200130950T patent/SI1311488T1/sl unknown
- 2001-08-08 HU HU0303763A patent/HUP0303763A3/hu unknown
- 2001-08-08 CA CA2419633A patent/CA2419633C/en not_active Expired - Fee Related
- 2001-08-08 EE EEP200300070A patent/EE200300070A/xx unknown
- 2001-08-08 ES ES01954264T patent/ES2334101T3/es not_active Expired - Lifetime
- 2001-08-14 PA PA20018525401A patent/PA8525401A1/es unknown
- 2001-08-15 UY UY26889A patent/UY26889A1/es not_active Application Discontinuation
- 2001-08-15 PE PE2001000815A patent/PE20020352A1/es not_active Application Discontinuation
- 2001-08-15 AR ARP010103900A patent/AR035580A1/es unknown
- 2001-08-16 TN TNTNSN01126A patent/TNSN01126A1/fr unknown
- 2001-08-16 SV SV2001000602A patent/SV2002000602A/es unknown
- 2001-08-16 AP APAP/P/2001/002250A patent/AP1375A/en active
- 2001-11-14 DO DO2001000233A patent/DOP2001000233A/es unknown
-
2002
- 2002-11-28 BG BG107330A patent/BG107330A/xx unknown
- 2002-11-28 IS IS6638A patent/IS6638A/is unknown
-
2003
- 2003-02-04 MA MA27025A patent/MA26940A1/fr unknown
- 2003-02-13 HR HR20030103A patent/HRP20030103A2/hr not_active Application Discontinuation
- 2003-02-14 NO NO20030706A patent/NO20030706L/no not_active Application Discontinuation
-
2008
- 2008-02-27 JP JP2008045382A patent/JP4778531B2/ja not_active Expired - Fee Related
-
2009
- 2009-12-30 CY CY20091101349T patent/CY1109693T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20030103A2 (en) | Substituted imidazoles as tafia inhibitors | |
AU2014272776C1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
ES2576579T3 (es) | Inhibidor de Fab I y proceso para su preparación | |
KR20160116017A (ko) | 보체 매개 질환의 치료를 위한 포스포네이트 화합물 | |
EP3761975A1 (en) | Cyanopyrrolidines as usp30 inhibitors and fibrosis treatment | |
SI9600177A (en) | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents | |
WO2010088000A2 (en) | Antifibrotic compounds and uses thereof | |
JP2003327532A (ja) | ペプチダーゼ阻害剤 | |
US20210253550A1 (en) | Therapeutic compounds and compositions | |
KR20020029653A (ko) | 피라지논 트롬빈 억제제 | |
HRP20040659A2 (en) | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors | |
US6521625B2 (en) | Pyrazinone thrombin inhibitors | |
US6949577B2 (en) | Pharmaceuticals | |
US7026324B2 (en) | Thrombin inhibitors | |
US20020147229A1 (en) | Pharmaceuticals | |
ZA200301230B (en) | Substituted imidazoles as tafia inhibitors. | |
CN104530030A (zh) | 噁唑烷酮类化合物及其在药物中的应用 | |
AU2003237012A1 (en) | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
OBST | Application withdrawn |